Уважаемые пользователи!

Данный сайт содержит информацию для людей с медицинским образованием и специалистов здравоохранения.
Входя на сайт, Вы подтверждаете свое согласие с Условиями использования и Политикой конфиденциальности.



Dear visitor!
This site contains medical information for healthcare professionals.
You can go further, if you agree with Terms and Conditions and Privacy Policy on this site.

Analysis of the calcium-phosphorus metabolism and function of the parathyroid glands in patients with type 1 diabetes mellitus

Cover Page

Abstract


Objective.
To analyze the calcium-phosphorus metabolism in patients with diabetes mellitus (DM) type 1 depending on the functional state of the kidneys.
Materials and Methods.
The study involved 235 patients with type 1 diabetic (males). One hundred and thirty-four patients entered the group without diabetic nephropathy (DN) and 101 patients entered the group with DN. To study the phosphorous-calcium metabolism in patients with type 1 diabetes there were studied the following parameters in blood plasma: the level of intact parathyroid hormone (PTH), total calcium (Ca), ionized calcium (Ca2+), serum phosphorus (P), as well as calculated CaxP product.
Results.
 In patients with type 1 diabetes in the progression of DN the increase of P was observed from stage 4 CKD and reduction of Ca ? from CKD stage 5. The increase of the level of PTH was observed from the stage of CKD 3, although isolated cases of secondary hyperparathyroidism were registered in patients with stage CKD 2. At the same time in a large group of the patients with type 1 diabetes there was observed level of PTH below the target values of the stages CKD 3, 4, 5. The deterioration of glycemic control in patients with type 1 diabetes is associated with decreased level of PTH. In patients with type 1 diabetes without DN and with DN there was observed inverse relationship between the level of glycated hemoglobin (HbA.
1c).
Conclusion.
In patients with type 1 diabetes the progression of DN leads to various disorders of phosphorus-calcium metabolism: reduction of Ca, higher level of P, alter the function of the parathyroid glands (secondary hyperparathyroidism and reduction of PTH below the target value). Deterioration of glycemic control in patients with type 1 diabetes is associated with a reduction of PTH.

Ekaterina Alexandrovna Khantakova

Irkutsk state medical University

Author for correspondence.
Email: hantakovaea@mail.ru

Russian Federation assistant of the Endocrinology and Clinical Pharmacology department

Larisa Yur'evna Khamnueva

Irkutsk state medical University

Email: hantakovaea@mail.ru

Russian Federation MD, PhD, Professor, Head of the Endocrinology and Clinical Pharmacology department

Galina Mikhailovna Orlova

Irkutsk state medical University

Email: hantakovaea@mail.ru

Russian Federation MD, PhD, Professor, Head of the Hospital therapy department

  1. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007;71(1):31–38.
  2. doi: 20.1038/sj.ki.5002009.
  3. Смирнов АВ, Волков ММ, Галкина ОВ, Жлоба АА, Эмануэль ВЛ. Взаимосвязь уровней витамина D, паратгормона, кальция, фосфатов крови у пациентов с хронической болезнью почек, не получающих терапию, замещающую функцию почек. Терапевтический архив. 2009;81(8):49–52. [Correlations between the levels of vitamin D, parathormone, calcium, blood phosphates in patients with chronic disease of the kidneys untreated with replacement renal therapy.Terapevticheskii arkhiv.2009;(8):49–52.]
  4. Wahl P, Xie H, Scialla J, Anderson CA, Bellovich K, Brecklin C, et al, Group CRICS. Earlier onset and greater severity of disordered mineral metabolism in diabetic patients with chronic kidney disease. Diabetes Care 2012;35(5):994–1001.
  5. doi: 10.2337/dc11-2235.
  6. Murakami R, Murakami S, Tsushima R, Ueda C, Mikami K, Ebina T, et al. Glycaemic control and serum intact parathyroid hormone levels in diabetic patients on haemodialysis therapy. Nephrol Dial Transplant 2007;23(1):315–320.
  7. doi: 10.1093/ndt/gfm639.
  8. Yamamoto T, Ozono K, Miyauchi A, Kasayama S, Kojima Y, Shima M, et al. Role of advanced glycation end products in adynamic bone disease in patients with diabetic nephropathy. Am. J. Kidney Dis 2001;38(4 Suppl 1):161. PubMed PMID: 11576945.
  9. Campos Pastor MM, Lopez-Ibarra PJ, Escobar-Jimenez F, Serrano Pardo MD, Garcia – Cervigon AG. Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: a prospective study. Osteoporosis International 2000;2000(11):455.
  10. Martinez I. Moina I, Montenegro J, Saracho R, Llach F. Is there a lesser hyperparathyroidism in diabetic patients with chronic renal failure. Nephrology Dialysis Transplantation 1998;13(Suppl 3):9–11.
  11. doi: 10.1093/ndt/13.suppl_3.9.
  12. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):1–266.
  13. Tomasello S. Secondary Hyperparathyroidism and Chronic Kidney Disease. Diabetes Spectrum. 2008;21(1):19–25.
  14. doi: 10.2337/diaspect.21.1.19.
  15. Sugimoto T, Ritter C, Morrissey J, Hayes C, Slatopolsky E. Effects of high concentrations of glucose on PTH secretion in parathyroid cells. Kidney Int. 1990;37(6):1522–1527.
  16. doi: 10.1038/ki.1990.144.
  17. Inaba M, Okuno S, Kumeda Y, Yamada S, Imanishi Y, Tabata T, et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. Clin J Am Soc Nephrol. 2007;18(3):896–903.
  18. Kalantar-Zadeh K, Kopple JD, Regidor DL, Jing J, Shinaberger CS, Aronovitz J, et al. A1C and survival in maintenance hemodialysis patients. Diabetes Care 2007;30(5):1049–1055.
  19. doi: 10.2337/dc06-2127.

Views

Abstract - 1243

PDF (Russian) - 651

HTML (Russian) - 918

PlumX


Copyright (c) 2013 Khantakova E.A., Khamnueva L.Y., Orlova G.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.